The Effect” puts that question onstage at the Jungle in a compelling fashion.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC ...

A decade after scientists at The Picower Institute for Learning and Memory at MIT first began testing whether sensory ...

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...

A decade after scientists in The Picower Institute for Learning and Memory at MIT first began testing whether sensory stimulation of the brain's 40Hz "gamma" frequency rhythms could treat Alzheimer's ...

A new generation of therapeutics looks beyond simply reengineering the gut microbiome to exploiting multiple pathways for novel microbiome and microbial applications.

Valbiotis unveils its annual financial statements and confirms its strategic and financial goals VALBIOTIS SA VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms ...

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.